Multiple sclerosis: Treating symptoms, and other general medical issues

Cleveland Clinic Journal of Medicine

Volumn 73, Issue 2, 2006, Pages 177-186

  Goldman, Myla D ^a   Cohen, Jeffrey A ^a   Fox, Robert J ^a,b   Bethoux, Francois A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; AMANTADINE; AMITRIPTYLINE; BACLOFEN; BETHANECHOL; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CARBAMAZEPINE; CORTICOSTEROID; DANTROLENE; ETIRACETAM; FLUOXETINE; GABAPENTIN; ISPAGULA; METHYLCELLULOSE; METHYLPHENIDATE; MODAFINIL; ONDANSETRON; OXCARBAZEPINE; OXYBUTYNIN; PEMOLINE MAGNESIUM; PHENYTOIN; PRIMIDONE; SOLIFENACIN; TERAZOSIN; TIZANIDINE; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZONISAMIDE;

ANOREXIA; ANTICHOLINERGIC EFFECT; ANTICIPATION; ATAXIA; BEHAVIOR MODIFICATION; BLADDER DYSFUNCTION; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DAILY LIFE ACTIVITY; DEPRESSION; DETRUSOR DYSSYNERGIA; DIARRHEA; DIETARY FIBER; DOCTOR PATIENT RELATION; DRUG WITHDRAWAL; ENTEROPATHY; EXERCISE; FATIGUE; FERTILITY; HEALTH CARE NEED; HEPATITIS; HUMAN; INDIVIDUALIZATION; INTERPERSONAL COMMUNICATION; LIFESTYLE; MEDICAL SPECIALIST; MENINX DISORDER; MULTIPLE SCLEROSIS; MUSCLE ATROPHY; MUSCLE WEAKNESS; MYALGIA; NAUSEA AND VOMITING; NEURALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; OSTEOPOROSIS; PAIN; PATIENT CARE; PATIENT REFERRAL; PHYSICIAN ATTITUDE; PHYSIOTHERAPY; PREGNANCY; QUALITY OF LIFE; REVIEW; SEIZURE; SENSORY DYSFUNCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SPASTICITY; STEREOTAXIC SURGERY; SYMPTOM; TREATMENT PLANNING; TREMOR; VACCINATION; VERTIGO; VISUAL IMPAIRMENT; DISABILITY;

ACTIVITIES OF DAILY LIVING; DISABILITY EVALUATION; HUMANS; MULTIPLE SCLEROSIS; QUALITY OF LIFE;

EID: 33644977855     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.2.177     Document Type: Review

References (65)

1. Stuart WH, editor. Current clinical perspectives on the treatment of multiple sclerosis. Neurology 2004; 63(suppl 5):S1-S42.
2. Fox RJ, Bethoux F, Goldman MD, Cohen JA. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. Cleve Clin J Med 2006; 73:91-102.
3. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: part II: quality of Life. Can J Neurol Sci 1998, 25:31-38.
4. Poser S, Wikstrom J, Bauer HJ. Clinical data and the identification of special forms of multiple sclerosis in 1271 cases studied with a standardized documentation system. J Neurol Sci 1979; 40:159-168.
5. Multiple Sclerosis Council for Clinical Practice Guidelines. Spasticity Management in Multiple Sclerosis. Clinical Practice Guidelines. Teaneck, NJ: Consortium of Multiple Sclerosis Centers, 2003.
6. Young RB, editor. Role of tizanidine in the treatment of spasticity. Neurology 1994; 44(suppl 9):S1-S80.
7. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis. Clinical Practice Guidelines. Teaneck, NJ: Consortium of Multiple Sclerosis Centers, 1998.
8. Goodin DS. Survey of multiple sclerosis in northern California. Mult Scler 1999, 5:77-88.
9. White LJ. Dressendorfer RH. Exercise and multiple sclerosis. Sports Med 2004; 34:1077-1100.
10. Pinto O, Polikar M, Debono G. Results of international clinic trials with lioresal. Postgrad Med J 1972; 48:18-23.
11. Feldman R, Kelly-Hayes M, Conomy J. et al. Baclofen for spasticity in multiple sclerosis: double-blind crossover and three-year study. Neurology 1978; 28:1094-1098.
12. Stempien L, Tsai T. Intrathecal baclofen pump use for spasticity. Am J Phys Med Rehabil 2000; 79:536-541.
13. Jarrett L, Siobhan M, Porter B. et al. Managing spasticity in people with multiple sclerosis: a goal-oriented approach to intrathecal baclofen therapy. Int J Mult Scler Care 2001; 3:10-21.
14. Sylvester A, Sadiq S. Long term use of intrathecal baclofen infusion in ambulatory patients with spasticity [Abstract]. Neurology 2001; 56:A26.
15. Bethoux F, Gogol D, Schwetz K, et al. Use of a registry on intrathecal baclofen therapy in a large multiple sclerosis center: analysis of data on 82 patients and proposed changes. Arch Phys Med Rehabil 2001; 82:1329.
16. Bass B, Weinshenker B, Rice G. Tizanidine versus baclofen in the treatment of multiple sclerosis patients. Acta Neurologica Scand 1988; 15:15-19.
17. Cutter NC, Scott DD, Johnson JC, et al. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000; 81:164-169.
18. Hawker K, Frohman E, Racke M. Levetiracetam for phasic spasticity in multiple sclerosis. Arch Neurol 2003; 60:1172-1174.
19. Bethoux F. Management of spasticity. In: Rudick RA, Goodkin DE, editors. Multiple Sclerosis Therapeutics. London: Martin Duniz, 2003:609-620.
20. Mayer NH, Simpson DH, editors. Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin. New York: We Move, 2002.
21. Bradley WE. Urinary bladder dysfunction in multiple sclerosis. Neurology 1978; 29:52-58.
22. Koldewijn EL, Homme OR, Lemmens WA, et al. Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol 1995; 154:169-173.
23. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003; 78:687-695.
24. Ho C. Transdermally-delivered oxybutynin (Oxytrol R) for overactive bladder. Issues Emerg Health Technol 2001; 24:1-4.
25. Brunton S. Kuritzky L. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin 2005; 21:71-80.
26. Betts CD, D'Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993; 56:245-250.
27. Chia YW, Fowler CJ, Kamm MA, et al. Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J Neurol 1995; 242:105-108.
28. Fisk J. Pontefract A, Ritvo P, et al. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994; 21:9-14.
29. Beran RG, Laetitia AA. Holland GJ. Pilot study: fatigue, sleep & MS [Abstract]. Neurology 2005; 65(suppl 1):P06.167.
30. Cohen R, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989; 46:676-680.
31. The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987; 14:273-278.
32. Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72:179-183.
33. Cephalon. Modafinil (Provigil) Package Insert. 2004.
34. Rossini RM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis: a results of a randomized, double blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 2001; 7:354-358.
35. Romani A, Bergamaschi R, Candeloro E, et al. Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment. Mult Scler 2004; 10:462-468.
36. Criscuolo S, Auletta C, Lippi S, et al. Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. Acta Neurol Scand 2005; 111:229-232.
37. Schulder M, Sernas TJ, Karimi R. Thalamic stimulation in patients with multiple sclerosis: long-term follow-up. Stereotact Funct Neurosurg 2003; 80:48-55.
38. Berk C, Carr J, Sinden M, et al. Thalamic deep brain stimulation for the treatment of tremor due to multiple sclerosis: a prospective study of tremor and quality of life. J Neurosurg 2002; 97:815-820.
39. Frohman E, Zhang H, Dewey RB, et al. Vertigo in MS: utility of positional and particle repositioning maneuvers. Neurology 2000; 55:1566-1568.
40. Frohman EM, Kramer PD, Dewey RB, et al. Benign paroxysmal positioning vertigo in multiple sclerosis: diagnosis, pathophysiology and therapeutic techniques. Mult Scler 2003; 9:250-255.
41. Amato MP, Ponziani G. Siracusa G, et al. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001; 58:1602-1606.
42. Rao SM, Leo GJ, Bernardin L, et al. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41:685-691.
43. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002; 59:674-678.
44. Sadovnick A, Eisen RN, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41:1193-1196.
45. Horner WG, Hurwitz H, Li DK, et al. Temporal lobe involvement in multiple sclerosis patients with psychiatric disorders. Arch Neurol 1987; 44:187-190.
46. Feinstein A, Roy P, Lobaugh N, Feinstein K, O'Connor P, Black S. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004; 62:586-590.
47. Schiffer RB. Management of psychiatric problems in patients with multiple sclerosis. Directions in Psychiatry 2001; 21:1-11.
48. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985; 312:1480-1482.
49. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by computerized data processing of 349 patients. Brain 1980; 103:281-300.
50. Roos KL, Flippen CC, Hingtgen C, et al. Neurologic disorders and pregnancy. Multiple sclerosis. Continuum 2000; 6:64-78.
51. Sandberg-Wollheim M, Frank D, Goodwin TM, et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 2005; 65:802-806.
52. Korn-Lubetzki I, Kahanna E, Cooper G, et al. Activity of multiple sclerosis during pregnancy and the puerperium. Ann Neurol 1984; 16:229-231.
53. Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 1998; 339:285-291.
54. Roullet E, Verdier-Taillefer MH, Amarenco P, et al. Pregnancy and multiple sclerosis; a longitudinal study of 125 remittent patients. J Neurol Neurosurg Psychiatry 1993; 56:1062-1065.
55. Birk K, Rudick RA. Pregnancy and multiple sclerosis. Arch Neurol 1986; 43:719-726.
56. Marrie RA. Environmental risk factors for multiple sclerosis aetiology. Lancet Neurol 2004; 3:709-718.
57. Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 344:327-332.
58. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343:1430-1438.
59. Multiple Sclerosis Council for Clinical Practice Guidelines. Immunizations and Multiple Sclerosis. Clinical Practice Guideline, 2001.
60. Cosman F, Nieves J, Komar L, et al. Fracture history and bone loss in patients with MS. Neurology 1998; 51:1161-1165.
61. Schwid SR, Goodman AD, Puzas JE, McDermott MP, Mattson DH. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 1996; 53:753-757.
62. Frediani B, Falsetti P, Bisogno S, et al. Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: A 12 month randomized prospective controlled study. J Rheumatol 2004; 31:1083-1087.
63. Zorzon M, Zivadinov R, Locatelli T, et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 2005; 12:550-556.
64. Crenshaw TL, Goldberg JP, Stern WC. Pharmacologic modification of psychosexual dysfunction. J Sex Marital Ther 1987; 13:239-252.
65. Slonimski M, Abram SE, Zuniga RE. Intrathecal baclofen and pain management. Reg Anesthes Pain Med 2004; 29:269-276.